



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number: 0 301 759 B1

(12)

EUROPEAN PATENT SPECIFICATION

(46) Date of publication of patent specification :
11.12.91 Bulletin 91/50

(51) Int. Cl.⁵ : A61L 25/00

(21) Application number : 88306666.4

(22) Date of filing : 20.07.88

(54) Bone cement for controlled release of substances.

(30) Priority : 30.07.87 US 79627

(43) Date of publication of application :
01.02.89 Bulletin 89/05

(45) Publication of the grant of the patent :
11.12.91 Bulletin 91/50

(84) Designated Contracting States :
AT BE CH DE ES FR GB GR IT LI LU NL SE

(66) References cited :
DE-A- 2 022 117
DE-A- 2 511 122
FR-A- 2 370 477
GB-A- 1 532 318

(73) Proprietor : Pfizer Hospital Products Group,
Inc.
235 East 42nd Street
New York New York 10017 (US)

(72) Inventor : Posey-Dowty, Jessica D.
196 Beechwood Avenue
Bogota, NJ (US)
Inventor : Higham, Paul A.
28 Valley Road
Ringwood, NJ (US)
Inventor : Arroyo, Nester
2 Chestnut Drive
East Windsor, NJ (US)
Inventor : Stark, Casper F.
2 Cambridge Road
Pompton Lakes, NJ (US)

(74) Representative : Bradbrook, Geoffrey William
et al
PFIZER LIMITED Ramsgate Road
Sandwich Kent, CT13 9NJ (GB)

EP 0 301 759 B1

Note : Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

Description

The present invention relates to a bone cement. More particularly, the present invention relates to a bone cement wherein a diagnostic or therapeutic agent is incorporated in the liquid component with the agent being incorporated by the use of an emulsifying agent.

Bone cements find wide usage in a variety of applications. For instance, they are used for cementing implants in place, for the anchoring of endoprostheses of the joints, in the treatment of skull defects, and for the performance of spinal fusion.

Typically, these bone cements are made by mixing together a powdered homopolymer or copolymer of methylmethacrylate and a suitable liquid monomer, usually methylmethacrylate in the presence of a catalyst system. Additionally, the bone cement may also contain x-ray contrast agents, such as barium sulfate or zirconium dioxide, or dyes for the identification of the bone cement in the body.

In usage, a doughy mixture is prepared from the two components which is then placed in the body and allowed to set *in situ* due to polymerization of the monomer. Polymerization of the monomer can be accelerated by the presence of a redox catalyst system, usually an organic peroxy compound, such as dibenzoyl peroxide, plus a reducing component, such as p-toluidine.

The placement of a foreign object, such as the bone cement or cemented prosthesis, requires that prophylactic measures be taken to guard against infection at the boundary surfaces found between the bone cement and bone, and/or between the bone, bone cement, and prosthesis. Such prophylactic measures have generally involved the addition of antibiotics to the one cement.

For instance, in United States Patent No. 4,059,684, the antibiotics which are added to the bone cement are the hydrohalides or sulfates of gentamicin in combination with sodium chloride, potassium chloride, sodium bromide or potassium bromide. In this patent, the antibiotic can be incorporated into either the powdered polymer or copolymer or the liquid monomer. No mention is made of the addition of an emulsifying agent to incorporate the antibiotic into the liquid monomer.

Other antibiotics which have been added to bone cement include penicillin and tetracycline, which in most instances, are added to the powdered polymer or copolymer.

In United Kingdom Patent No. 1,532,318, the methylmethacrylate liquid monomer is present as an emulsion in water. No mention is made of the incorporation of antibiotics into this monomer.

In all situations wherein an antibiotic is added to a bone cement, the initial release is in a relatively high concentration to assure its bactericidal and bacterio-

tatic action. After this initial release, a diminution of the concentration takes place with the release rate, which is now lower, remaining relatively constant over a longer period of time. The net result is that even though the antibiotic release is sustained, the active concentration of the antibiotic is low. Thus, early infections may be prevented but later infections may not be reliably prevented or combatted. As is known, increasing the concentration of antibiotic may impair the mechanical strength of the bone cement so there remains a need for a bone cement from which the antibiotic will be released at both a sustained rate and at a high concentration.

Fig. 1 is a graph showing the concentration of released erythromycin over a sustained time period from a bone cement of the present invention.

The present invention is directed to a bone cement comprising the combination of components A and B wherein :

Component A comprises a powdered polymer or copolymer of an acrylic ester and,

Component B comprises a liquid monomer of an acrylic ester containing (a) a diagnostic or therapeutic substance, and (b) an emulsifying agent for said diagnostic or therapeutic substance, whereby the incorporation of said diagnostic or therapeutic substance in the bone cement composition is substantially in component B.

Preferred powdered polymers or copolymers of acrylic esters include methacrylates, methylmethacrylates and copolymers of methylmethacrylate and styrene.

Preferred liquid monomers of acrylic esters include methylmethacrylates.

Prepared substances include therapeutic substances such as erythromycin, gentamicin, or colistin, combinations thereof, or pharmaceutically acceptable salts thereof. Most preferred are pharmaceutically acceptable salts of erythromycin.

Preferred emulsifying agents include sorbitan mono oleate polyoxyethylene and sodium dihexyl succinate.

Another aspect of the present invention is the liquid monomer of an acrylic ester containing the diagnostic or therapeutic substance and an emulsifying agent for said substance.

The present invention provides a composition for the preparation of a bone cement from which, e.g., an antibiotic will be released in a sustained high concentration.

The first component of the composition comprises a powdered polymer or copolymer of an acrylic ester. By the term "polymer or copolymer of an acrylic ester" is meant a polymer of an acrylate, e.g. a methacrylate, polymethylmethacrylate etc., as well as copolymers of the above compounds with non-acrylates, for example, such as methyl methacrylate-styrene copolymers. In addition, the powder component

may contain an x-ray contrast agent such as barium sulfate or zirconium dioxide. If present, these x-ray contrast agents, especially barium sulfate, are added in the amount of about 5 to 15 weight percent with respect to the powdered polymer or copolymer. A catalyst, typically benzoyl peroxide, may also be incorporated in the powdered polymer or copolymer, in which case a reducing agent, for example, dimethyl p-toluidine, would be incorporated in the liquid monomer. Alternatively, the powdered polymer or copolymer may contain a reducing agent, in which case a peroxide catalyst would be incorporated in the liquid monomer.

The second component of the bone cement composition comprises a liquid monomer of an acrylic ester containing (a) a diagnostic or therapeutic substance and (b) an emulsifying agent for said diagnostic or therapeutic substance. This results in the incorporation of the diagnostic or therapeutic substance present in the bone cement composition being substantially in component B. By "substantially" is meant that at least 75% of the diagnostic or therapeutic substance in the composition is in component B. Higher ranges can also be used with as much as 80-90% of the diagnostic or therapeutic substance being incorporated in component B. In a preferred case, 100 percent of the diagnostic or therapeutic agent in the bone cement composition can be incorporated in component B. A preferred liquid monomer of an acrylic ester is methylmethacrylate. In the present invention, it has surprisingly been found that incorporation of the diagnostic or therapeutic agent into the liquid monomer by means of the emulsifying agent leads to a high sustained concentration of the diagnostic or therapeutic substance over time. The remainder of the specification will discuss the increased concentration of therapeutic substances, especially antibiotics, but is to be understood that the discussion applies equally well to diagnostic substances, such as radioactive tracers, etc., as well as other classes of therapeutic substances such as anti-cancer drugs, anti-inflammatory drugs, immunosuppressants, immunosuppressants, osteogenesis promoters, etc.

In the present invention, a major proportion of the antibiotic is preferably incorporated in the liquid monomer by means of an emulsifying agent. This results in a number of advantages over the previously known methods in which the antibiotics were compounded with the powder component of the cement. One problem associated with this method was the requirement that there be proper mixing of the therapeutic agent with the powder component with homogeneous dispersion of the antibiotic and elimination of aggregates. Such results were not always achieved. Other requirements for the effective release of the therapeutic substance into the liquid monomer; namely the requirement of a large surface area for the

diffusion of water from the surrounding tissues into the cement mantle and the requirement that the substance contained in the cement mantle be soluble in the liquid containing the substance, are eliminated. The liquid which does get transported out of the cement mantle into the surrounding tissue contains the desired substance. Thus, a number of advantages are apparent.

Examples of antibiotics which can be incorporated into the liquid monomer are erythromycin, gentamicin, colistin, penicillin, Terramycin, Aureomycin, Vibramycin, etc. Especially preferred antibiotics are erythromycin, gentamycin and colistin. The concentration of antibiotic which may be incorporated into the liquid monomer ranges from about 0.03 to about 8.0 weight percent, based on the liquid monomer. Of course, those skilled in the art to which this invention applies will recognize that, depending upon the activity of the antibiotic, higher or lower ranges can also be used.

In the present invention, the antibiotic, or other diagnostic or therapeutic agent, is incorporated into the liquid monomer by means of an emulsifying agent. An especially preferred emulsifying agent is sorbitan monooleate polyoxyethylene, also known as Tween 80. Another preferred emulsifying agent is sodium dihexyl sulfosuccinate. Other emulsifying agents which can be used in the present invention are polyoxyethylenesorbitanmonopalmitate, polyoxyethylenesorbitanmonostearate and polyoxyethylenesorbitanmonooleate. In addition to stabilizing the therapeutic substance in the liquid monomer, the emulsifying agent also possibly serves to dissipate the heat formed during the exothermic polymerization of the monomer. In the present invention, the emulsifying agent is present in an amount ranging from about 0.1 to about 10.0 weight percent, based on the liquid monomer.

In formulating the liquid monomer/therapeutic substance component of the present invention, the order of mixing of the ingredients is not critical. For instance, the antibiotic, for example, may be dissolved in water, if it is water soluble, and the emulsifying agent can be added to the dissolved antibiotic. The emulsified antibiotic can then be added to the liquid monomer. If the antibiotic is soluble in the liquid monomer, the antibiotic may be added to the monomer containing the emulsifying agent or the antibiotic mixed with the emulsifying agent may be added to the liquid monomer.

While the invention has been described with relation to a bone cement comprising the combination of the powdered polymer or copolymer and the liquid monomer containing the diagnostic or therapeutic substance plus the emulsifying agent, it will be apparent that the liquid monomer itself containing the emulsifier and diagnostic or therapeutic substance is also contemplated as being another aspect of the pre-

sent invention. This liquid monomer/therapeutic or diagnostic substance/emulsifying agent composition can be used as a foreproduct for bone cement. Accordingly, such composition also forms a part of the present invention.

The present invention is illustrated by the following examples, which are not to be construed as limiting the invention, the scope of which is to be determined by the appended claims.

Bone cements of the invention are made by adding the following indicated liquid components to a powder component containing a radiopacifier. The cement is hand-mixed in a conventional manner for known bone cement. The following examples give the method of preparing the liquid component to be mixed with the powdered component.

Example 1

The liquid component was prepared by mixing the following ingredients in the order given. The components were mixed in a resealable polyethylene container until all were evenly dispersed.

1. 3.655 g erythromycin gluceptate
2. 17.8 g water
3. 1.8 ml Tween 80
4. 100 ml of Methyl methacrylate monomer (97.4% v/v), (containing also 2.5 ml N, N-dimethyl-para-toluidine (2.6% v/v) and 75 ± 15 ppm hydroquinone).

One fifth of this mixture was added per dose of the powder component, 40 g, (containing 6.0 g Polymethyl methacrylate (15% w/w), 30.0 g of Methyl methacrylate-styrene-copolymer (75% w/w) and 4.0 g Barium Sulfate U.S.P. (10% w/w)) and hand-mixed to form the bone cement.

Example 2

Another liquid component was prepared by adding the following ingredients in the order given in the same way as Example 1.

1. 1.5 g erythromycin gluceptate
2. 7.08 g water
3. 0.7 ml Tween-80
4. 40.0 ml Methyl methacrylate (97.4% v/v Methyl methacrylate, 2.6% v/v N, N-dimethyl-para-toluidine, 75 ± 15 ppm hydroquinone).

Two doses of the powder component (80 g) containing 12.0 g Polymethyl methacrylate (15% w/w), 60.0 g Methyl methacrylate-styrene-copolymer (75% w/w), 8 g Barium Sulfate U.S.P. (10% w/w) were hand-mixed with the liquid to form the cement.

Example 3

Another liquid component was prepared by adding the following ingredients in the order given.

1. 0.731 g erythromycin gluceptate
2. 2.07 g water
3. 3.2 g Aerosol MA-80
4. 40.0 ml Methyl methacrylate (containing 97.4% v/v Methyl methacrylate, 2.6% v/v N, N-dimethyl-para-toluidine(2.6%) and 75 ± 15 ppm of hydroquinone).
5. 0.731 g erythromycin gluceptate

Two doses (80 g) of powder component containing 15% w/w Polymethyl methacrylate w/w, 75% w/w Methyl methacrylate-Styrene-copolymer and 10% Barium Sulfate U.S.P.) were hand-mixed with the above liquid component to form the cement.

Example 4

The following ingredients were mixed in the order given.

1. 1.670 g gentamicin sulfate
2. 7.440 g water
3. 0.763 g Tween-80
4. 40.0 ml Methyl methacrylate (containing 97.4% v/v Methyl methacrylate, 2.6% v/v N, N-dimethyl-para-toluidine, and 75 ± 15 ppm hydroquinone)
5. 2.11 g liquid component in Example 1

The liquid component was added to the powder component, 80 g, (containing 15% w/w Polymethyl methacrylate, 75% w/w Methyl methacrylate-Styrene-copolymer and 10% w/w Barium Sulfate, U.S.P.) and hand-mixed to form the cement.

Claims

Claims for the following Contracting States : AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE

1. A bone cement composition comprising the combination of components A and B wherein :

Component A comprises a powdered polymer or copolymer of an acrylic ester and, Component B comprises a liquid monomer of an acrylic ester containing (a) a diagnostic or therapeutic substance and (b) an emulsifying agent for said diagnostic or therapeutic substance, whereby the incorporation of said diagnostic or therapeutic substance in the bone cement composition is substantially in component B.

2. The bone cement of claim 1 wherein component A is polymethyl methacrylate.

3. The bone cement of claim 1 wherein component A is a copolymer of methylmethacrylate and styrene.

4. The bone cement of claim 1 wherein component B is methylmethacrylate.

5. The bone cement of claim 1 wherein component B contains a therapeutic substance.

6. The bone cement of claim 5 wherein said

therapeutic substance is an antibiotic.

7. The bone cement of claim 6 wherein said antibiotic is selected from the group consisting of erythromycin, gentamicin, and colistin, or pharmaceutically acceptable salts thereof.

8. The bone cement of claim 7 wherein said antibiotic is erythromycin.

9. The bone cement of claim 1 wherein said emulsifying agent is sorbitan mono-oleate polyoxyethylene.

10. The bone cement of claim 7 wherein said emulsifying agent is sodium dihexyl sulfosuccinate.

11. A liquid monomer of an acrylic ester containing (a) a diagnostic or therapeutic substance and (b) an emulsifying agent for said substance.

12. The monomer of claim 11 wherein said therapeutic substance is erythromycin, or a pharmaceutically acceptable salt thereof.

Claims for the following Contracting States : ES, GR

1. A process for the production of a bone cement composition comprising combining

(a) A powdered polymer or copolymer of an acrylic ester ; and

(b) a liquid monomer of an acrylic ester, said liquid monomer containing a diagnostic or therapeutic substance and an emulsifying agent for said diagnostic or therapeutic substance, whereby the incorporation of said diagnostic or therapeutic substance in the bone cement composition is substantially in component B.

2. The process of claim 1 wherein component A is polymethyl methacrylate.

3. The process of claim 1 wherein component A is a copolymer of methylmethacrylate and styrene.

4. The process of claim 1 wherein component B contains a therapeutic substance.

5. The process of claim 4 wherein said therapeutic substance is an antibiotic.

6. The process of claim 5 wherein said antibiotic is erythromycin, or a pharmaceutically acceptable salt thereof.

7. The process of claim 1 wherein said emulsifying agent is sorbitan mono-oleate polyoxyethylene.

8. A process for the incorporation of a diagnostic or therapeutic substance into a liquid monomer of an acrylic ester comprising incorporating said diagnostic or therapeutic agent into said liquid monomer by means of an emulsifying agent.

9. The process of claim 8 wherein said therapeutic substance is erythromycin, or a pharmaceutically acceptable salt thereof.

Patentansprüche

Patentansprüche für folgende

**Vertragsstaaten : AT, BE, CH, DE, FR, GB,
IT, LI, LU, NL, SE**

1. Knochenzementzusammensetzung umfassend die Kombination der Komponenten A und B, wobei

10 Komponente A ein pulverförmiges Polymer oder Copolymer eines Acrylsäureesters und

Komponente B ein flüssiges Monomer eines Acrylsäureesters, enthaltend (a) eine diagnostische oder therapeutische Substanz und (b) ein Emulgiermittel für die diagnostische oder therapeutische Substanz umfaßt, wobei die diagnostische oder therapeutische Substanz in der Knochenzementzusammensetzung im wesentlichen in der Komponente B inkorporiert ist.

15 2. Knochenzement nach Anspruch 1, wobei Komponente A Polymethylmethacrylat ist.

3. Knochenzement nach Anspruch 1, wobei Komponente A ein Copolymer von Methylmethacrylat und Styrol ist.

20 4. Knochenzement nach Anspruch 1, wobei Komponente B Methylmethacrylat ist.

5. Knochenzement nach Anspruch 1, wobei Komponente B eine therapeutische Substanz enthält.

30 6. Knochenzement nach Anspruch 5, wobei die therapeutische Substanz ein Antibiotikum ist.

7. Knochenzement nach Anspruch 6, wobei das Antibiotikum aus der Gruppe bestehend aus Erythromycin, Gentamicin und Colistin, oder pharmazeutisch annehmbaren Salzen hievon, ausgewählt ist.

35 8. Knochenzement nach Anspruch 7, wobei das Antibiotikum Erythromycin ist.

9. Knochenzement nach Anspruch 1, wobei das Emulgiermittel Sorbitanmonooleatpolyoxyethylen ist.

10. Knochenzement nach Anspruch 7, wobei das Emulgiermittel Natriumdihexylsulfosuccinat ist.

40 11. Flüssiges Monomer eines Acrylsäureesters enthaltend (a) eine diagnostische oder therapeutische Substanz und (b) ein Emulgiermittel für diese Substanz.

45 12. Monomer nach Anspruch 11, wobei die therapeutische Substanz Erythromycin oder ein pharmazeutisch annehmbares Salz hievon ist.

Patentansprüche für folgende

Vertragsstaaten : ES, GR

1. Verfahren zur Herstellung einer Knochenzementzusammensetzung, umfassend das Kombinieren

55 eines pulverförmigen Polymeren oder Copolymeren eines Acrylsäureesters und eines flüssigen Monomers eines Acrylsäureesters, wobei das flüssige Monomer eine diagno-

- stische oder therapeutische Substanz und ein Emulgiermittel für die diagnostische oder therapeutische Substanz enthält, wobei die diagnostische oder therapeutische Substanz in der Knochenzementzusammensetzung im wesentlichen in der Komponente B inkorporiert ist.
2. Verfahren nach Anspruch 1, wobei Komponente A Polymethylmethacrylat ist.
3. Verfahren nach Anspruch 1, wobei Komponente A ein Copolymer von Methylmethacrylat und Styrol ist.
4. Verfahren nach Anspruch 1, wobei Komponente B eine therapeutische Substanz enthält.
5. Verfahren nach Anspruch 4, wobei die therapeutische Substanz ein Antibiotikum ist.
6. Verfahren nach Anspruch 5, wobei das Antibiotikum Erythromycin oder ein pharmazeutisch annehmbares Salz davon ist.
7. Verfahren nach Anspruch 1, wobei das Emulgiermittel Sorbitanmonooleatpolyoxyethylen ist.
8. Verfahren zum Einarbeiten einer diagnostischen oder therapeutischen Substanz in ein flüssiges Monomer eines Acrylsäureesters, umfassend das Einarbeiten des diagnostischen oder therapeutischen Mittels in das flüssige Monomer mittels eines Emulgiermittels.
9. Verfahren nach Anspruch 8, wobei die therapeutische Substanz Erythromycin oder ein pharmazeutisch annehmbares Salz davon ist.
- Revendications**
- Revendications pour les Etats contractants suivants : AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE**
1. Composition de ciment pour les os, comprenant des constituants A et B en association, dans laquelle :
- le constituant A consiste en une poudre d'un polymère ou copolymère d'un ester acrylique, et le constituant B consiste en un monomère liquide d'un ester acrylique contenant (a) une substance de diagnostic ou une substance thérapeutique et (b) un agent émulsionnant pour ladite substance de diagnostic ou substance thérapeutique, ladite substance de diagnostic ou substance thérapeutique présente dans la composition de ciment pour les os étant ainsi essentiellement incorporée au constituant B.
2. Ciment pour les os suivant la revendication 1, dans lequel le constituant A est le polyméthacrylate de méthyle.
3. Ciment pour les os suivant la revendication 1, dans lequel le constituant A est un copolymère de méthacrylate de méthyle et de styrène.
4. Ciment pour les os suivant la revendication 1,
5. dans lequel le constituant B est le méthacrylate de méthyle.
6. Ciment pour les os suivant la revendication 1, dans lequel le constituant B contient une substance thérapeutique.
7. Ciment pour les os suivant la revendication 5,
8. dans lequel la substance thérapeutique est un antibiotique.
9. Ciment pour les os suivant la revendication 6,
10. dans lequel l'antibiotique est choisi dans le groupe comprenant l'érythromycine, la gentamycine et la colistine ou leurs sels pharmaceutiquement acceptables.
11. Ciment pour les os suivant la revendication 7, dans lequel l'antibiotique est l'érythromycine.
12. Ciment pour les os suivant la revendication 1, dans lequel l'agent émulsionnant est un mono-oléate de sorbitane-polyoxyéthylène.
13. Ciment pour les os suivant la revendication 7,
14. dans lequel l'agent émulsionnant est le dihexylsulfosuccinate de sodium.
15. Monomère liquide d'un ester acrylique contenant (a) une substance de diagnostic ou une substance thérapeutique et (b) un agent émulsionnant pour ladite substance.
16. Monomère suivant la revendication 11, dans lequel la substance thérapeutique est l'érythromycine ou un de ses sels pharmaceutiquement acceptables.
- Revendications pour les Etats contractants suivants : ES, GR**
1. Procédé de production d'une composition de ciment pour les os, consistant à mélanger
- (a) une poudre d'un polymère ou copolymère d'un ester acrylique ; et
- (b) un monomère liquide d'un ester acrylique, ledit monomère liquide contenant une substance de diagnostic ou substance thérapeutique et un agent émulsionnant pour ladite substance de diagnostic ou substance thérapeutique, ladite substance de diagnostic ou substance thérapeutique présente dans la composition de ciment pour les os étant ainsi incorporée essentiellement au constituant B.
2. Procédé suivant la revendication 1, dans lequel le constituant A est le polyméthacrylate de méthyle.
3. Procédé suivant la revendication 1, dans lequel le constituant A est un copolymère de méthacrylate de méthyle et de styrène.
4. Procédé suivant la revendication 1, dans lequel le constituant B contient une substance thérapeutique.
5. Procédé suivant la revendication 4, dans lequel la substance thérapeutique est un antibiotique.
6. Procédé suivant la revendication 5, dans lequel l'antibiotique est l'érythromycine ou un de ses sels pharmaceutiquement acceptables.

7. Procédé suivant la revendication 1, dans lequel l'agent émulsionnant est un mono-oléate de sorbitane-polyoxyéthylène.

8. Procédé pour l'incorporation d'une substance de diagnostic ou substance thérapeutique à un monomère liquide d'un ester acrylique, consistant à incorporer ladite substance de diagnostic ou substance thérapeutique audit monomère liquide au moyen d'un agent émulsionnant.

9. Procédé suivant la revendication 8, dans lequel la substance thérapeutique est l'érythromycine ou un de ses sels pharmaceutiquement acceptables.

5

10

15

20

25

30

35

40

45

50

55

7

